FDA accepts supplemental new drug application for Ameluz PDT (aminolevulinic acid hydrochloride) in superficial basal cell carcinoma – Biofrontera
Biofrontera Inc. announced that the FDA has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical… read more.
